NCT05739435Active, not recruitingPhase 2
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- First submitted
- 2 Feb 2023
- Start date
- 17 Jan 2023
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Alumis Inc
- Diseases
- Psoriasis
- NCT number
- NCT05739435
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 165
- From 17 Jan 2023 to the primary completion date, 1 Dec 2027
- 38 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received a prohibited concomitant medication
Other
- Pregnancy
Who the study is looking for
- Must have completed a prior ESK-001 study
- Men and Women must use highly effective methods of contraception for the entirety of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (38)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.